{
    "clinical_study": {
        "@rank": "80530", 
        "arm_group": [
            {
                "arm_group_label": "Aripiprazole and aripiprazole once-monthly", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Paliperidone and paliperidone palmitate", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the effectiveness of aripiprazole once-monthly in the maintenance treatment of\n      patients with a diagnosis of schizophrenia as defined by the Diagnostic and Statistical\n      Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR\u00ae), in a naturalistic care\n      setting by comparing it to an existing long-acting antipsychotic, paliperidone palmitate."
        }, 
        "brief_title": "Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia", 
        "condition": "Schizophrenia", 
        "condition_browse": {
            "mesh_term": "Schizophrenia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patient has schizophrenia, diagnosed according to DSM-IV-TR\u00ae.\n\n          -  The patient has a CGI-S score from mildly ill to markedly ill at the Screening and\n             Baseline Visit(s).\n\n          -  The patient is in need of a change in the current antipsychotic treatment and in the\n             judgement of the investigator the patient would benefit from an extended treatment\n             with a once-monthly formulation.\n\n          -  The patient agrees to protocol-defined use of effective contraception.\n\n        Exclusion Criteria:\n\n          -  The patient has any current psychiatric disorder or Axis I disorder (DSM-IV\u00ae\n             criteria) other than schizophrenia established as the primary diagnosis.\n\n          -  The patient is experiencing acute exacerbation of psychotic symptoms at the Screening\n             Visit or between the Screening and Baseline Visits.\n\n          -  The patient in the investigator's judgment has shown significant intolerance and/or\n             lack of efficacy to oral aripiprazole, paliperidone or risperidone.\n\n          -  The patient is at significant risk of harming himself/herself or others according to\n             the investigator's judgement or according to Columbia-Suicide Severity Rating Scale\n             (C-SSRS).\n\n          -  The patient has a history of neuroleptic malignant syndrome.\n\n          -  The patient has any relevant medical history or current presence of systemic disease\n\n          -  The patient is, in the investigator's opinion, unlikely to comply with the protocol\n             or is unsuitable for any reason.\n\n        Other inclusion and exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "286", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01795547", 
            "org_study_id": "14724A", 
            "secondary_id": "2012-002785-12"
        }, 
        "intervention": [
            {
                "arm_group_label": "Aripiprazole and aripiprazole once-monthly", 
                "description": "Oral aripiprazole tablets according to Summary of Product Characteristics (SmPC)/United States Prescription Information (USPI) daily for 4 weeks followed by the 1st aripiprazole intramuscular (IM) injection. Oral tablets will be taken for 2 more weeks after the 1st injection. Additional injections every 4 weeks until Week 24", 
                "intervention_name": "Aripiprazole and aripiprazole once-monthly", 
                "intervention_type": "Drug", 
                "other_name": "Abilify\u00ae"
            }, 
            {
                "arm_group_label": "Paliperidone and paliperidone palmitate", 
                "description": "Oral paliperidone tablets according to SmPC/USPI daily for 3 weeks followed by paliperidone palmitate IM injections every 4 weeks with last dose at Week 24 according to SmPC/USPI", 
                "intervention_name": "Paliperidone and paliperidone palmitate", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Paliperidone: Invega\u00ae", 
                    "Paliperidone palmitate: Xeplion\u00ae, or Invega\u00ae, or Sustenna\u00ae"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "9-hydroxy-risperidone", 
                "Aripiprazole"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90660"
                    }, 
                    "name": "US002"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92102"
                    }, 
                    "name": "US006"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A 28-week, Randomised, Open-label Study Evaluating the Effectiveness of Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia", 
        "overall_contact": {
            "email": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S"
        }, 
        "overall_official": {
            "affiliation": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "Czech Republic: State Institute for Drug Control", 
                "Estonia: The State Agency of Medicine", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Italy: The Italian Medicines Agency", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Sweden: Medical Products Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Quality of Life Scale (QLS) total score", 
            "measure": "Mean change from Baseline in quality of life", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Week 28"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01795547"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Investigator's Assessment Questionnaire (IAQ) total score", 
                "measure": "Investigator's assessment of overall effectiveness", 
                "safety_issue": "No", 
                "time_frame": "Week 28"
            }, 
            {
                "description": "Clinical Global Impression - Severity of Illness (CGI-S) score", 
                "measure": "Mean change from Baseline in clinical global impression", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 28"
            }, 
            {
                "description": "4 QLS dimension scores", 
                "measure": "Mean change from Baseline in quality of life using QLS", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 28"
            }, 
            {
                "description": "Subjective Well-being under Neuroleptics - short version (SWN-S) total score", 
                "measure": "Mean change from Baseline in subjective well-being using SWN-S", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 28"
            }, 
            {
                "description": "Tolerability and Quality of Life (TooL) total score", 
                "measure": "Mean change from Baseline in tolerability and quality of life using TooL", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 28"
            }, 
            {
                "description": "Number of adverse events", 
                "measure": "Safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 28 weeks and 4-week safety follow up"
            }, 
            {
                "description": "Columbia-Suicide Severity Rating Scale (C-SSRS) score", 
                "measure": "Risk of suicidality", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 28 weeks and 4-week safety follow up"
            }
        ], 
        "source": "H. Lundbeck A/S", 
        "sponsors": {
            "collaborator": {
                "agency": "Otsuka Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "H. Lundbeck A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}